Outpatient low-dose venetoclax-azacitidine vs intensive therapy in newly diagnosed AML in resource-limited settings
Authors:
- Fernando De la Garza-SalazarFGFernando De la Garza-Salazar
- Yadith Karina Lopez-GarciaYLYadith Karina Lopez-Garcia
- Alexis De la Rosa-FloresARAlexis De la Rosa-Flores
- Paulo Ugarte-PeláezPUPaulo Ugarte-Peláez
- Juan Carlos Olivares-GazcaJOJuan Carlos Olivares-Gazca
- Guillermo Ruiz-ArgüellesGRGuillermo Ruiz-Argüelles
- David Gómez-AlmaguerDGDavid Gómez-Almaguer
- Andrés Gómez-De LeónALAndrés Gómez-De León
Open Access
- 6 November 2025
- journal article
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (1)
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxClinical Lymphoma Myeloma and Leukemia, 2025
- Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemiaAnnals of Hematology, 2024
- Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSBlood Neoplasia, 2024
- Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 studyLeukemia Research, 2023
- Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAmerican Journal of Hematology, 2023
- Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAnnals of Hematology, 2023
- Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer PerspectivePharmacoEconomics, 2022
- Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemiaJournal of Cancer Research and Clinical Oncology, 2022
- Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National RegistryClinical Lymphoma Myeloma and Leukemia, 2020
- Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American CenterClinical Lymphoma Myeloma and Leukemia, 2018